Evidence map›Paper›PMID 40932612›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Enhancing interpretability of AI with radiomics-based deep neural network: proof of concept in the classification of Parkinsonian syndromes with

Chenyang Li, Fangyang Jiao, Shaoyou Wu, Chenhan Wang, Min Wei, Shuoyan Zhang, Luyao Wang, Yu Huang, Yafu Yin, Rong Tian and 9 more

Abstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Chenyang Li *Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Fangyang Jiao *Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Shaoyou WuInstitute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Chenhan WangInstitute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Min WeiDepartment of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Shuoyan ZhangSchool of Communication and Information Engineering, Shanghai University, Shanghai, China.
Luyao WangInstitute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Yu HuangInstitute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Yafu YinDepartment of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Rong TianDepartment of Nuclear Medicine, West China Hospital, Sichuan University, Sichuan, China.
Alexander BernhardtDepartment of Neurology, University Hospital, LMU Munich, Munich, Germany.
Sabrina KatzdoblerDepartment of Neurology, University Hospital, LMU Munich, Munich, Germany.
Johannes LevinDepartment of Neurology, University Hospital, LMU Munich, Munich, Germany.
Günter U HöglingerDepartment of Neurology, University Hospital, LMU Munich, Munich, Germany.
Matthias BrendelGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Axel RomingerDepartment of Nuclear Medicine, University Hospital Bern, Bern, Switzerland.
Kuangyu ShiDepartment of Nuclear Medicine, University Hospital Bern, Bern, Switzerland. kuangyu.shi@unibe.ch.
Chuantao ZuoHuman Phenome Institute, Fudan University, Shanghai, China. zuochuantao@fudan.edu.cn.
Jiehui JiangInstitute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China. jiangjiehui@shu.edu.cn.ORCID 0000-0003-4948-3683

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveInterpretability and reproducibility remain major challenges in applying deep neural network (DNN) to neuroimaging-based diagnosis. This study proposes a radiomics-guided dual-channel deep neural network (RDDNN) to improve feature transparency and enhance clinical understanding in the classification of Parkinsonian syndromes.

methodsIn this bi-centric study, we analysed two independent cohorts comprising 1,275 patients with idiopathic Parkinson's disease (IPD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP), alongside 223 healthy controls from Huashan Hospital and 90 patients with IPD, MSA, and PSP (34IPD, 17MSA, 39PSP) from the University Hospital Munich. It is a re-analysis of well-studied Chinese and German cohorts of

resultsIn the internal blind-test cohort, the RDDNN achieved high accuracy (AUC = 0.99, accuracy = 0.98). SHAP and correlation analyses jointly indicated complementary information across channels, some of which were clinically interpretable. In the external cohort, the model maintained robust performance (AUC = 0.94, accuracy = 0.81), with consistent feature patterns across populations. The model significantly reduced evaluation time compared to nuclear medicine specialists' readings (p < 0.001), and the heatmaps showed disease-specific activation in anatomically relevant regions for IPD, MSA, and PSP.

conclusionThe RDDNN framework provides a clinically interpretable and reproducible DNN solution for classifying Parkinsonian disorders. By integrating radiomics and attention-based modeling, it enhances lesion localization, supports clinical decision-making, and offers performance comparable to human specialists-while substantially improving diagnostic efficiency.

Indexed as

Deep LearningFluorodeoxyglucose F18Image Processing, Computer-AssistedNeural Networks, ComputerParkinsonian DisordersPositron-Emission TomographyAgedFemaleHumansMaleMiddle AgedProof of Concept StudyRadiomicsFluorodeoxyglucose F1818F-fluorodeoxyglucosePET imagingDual-channel neural networkModel interpretabilityParkinsonian syndromesRadiomicsSHAP

Identifiers

PMID40932612
PMCPMC12860829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.